Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy.
A novel combination of culturing and DNA-based terminal restriction fragment length polymorphism (TRFLP) analysis was used to investigate the effect of probiotics on antibiotic-induced gut microbiota alterations to determine if a probiotic preparation containing bifidobacteria and lactobacilli, taken during and after antibiotic therapy, can minimize antibiotic disturbance of faecal microbiota. Healthy subjects administered amoxicillin/clavulanate were randomized and concomitantly received a placebo or probiotic mixture. The primary end point was similarity of faecal microbiota as determined by culturing and TRFLP from subjects taking probiotics compared to those taking a placebo measured by comparing data from baseline to post-treatment for each subject. TRFLP analysis revealed a high subject to subject variation in the baseline faecal microbiota. The most common antibiotic-induced disturbance was a relative increase in Clostridium, Eubacterium, Bacteroides and Enterobacteraceae. The mean similarity to the baseline increased over time in both treatment groups, although the probiotic group was less disturbed according to both TRFLP and culture data. The culture method revealed that post-antibiotic faecal microbiota in probiotic-consuming subjects were more similar to the baseline microbiota than the control group (P=0.046). Changes in Enterobactereaceae (P=0.006) and Bifidobacterium (P=0.030) counts were significantly different between the groups. Analysis of TRFLP data reinforced the trend between groups but was not statistically significant (P=0.066). This study indicates this mixture of probiotics promotes a more rapid return to pre-antibiotic baseline faecal bacterial microbiota.
Engelbrektson
Anna
A
Department of Energy Joint Genome Institute, Walnut Creek, CA, USA.
Korzenik
Joshua R
JR
Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Pittler
Arlyn
A
Division of Gastroenterology, Washington University School of Medicine, St Louis, MO, USA.
Sanders
Mary E
ME
Dairy and Food Culture Technologies, Centennial, CO, USA.
Klaenhammer
Todd R
TR
North Carolina State University, Raleigh, NC, USA.
Leyer
Gregory
G
Cultures Division R&D, Danisco, Madison, WI, USA.
Kitts
Christopher L
CL
Environmental Biotechnology Institute, California Polytechnic State University, San Luis Obispo, CA, USA.
D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001439:Bacteroides / Q000187:drug effects / Q000235:genetics; D001644:Bifidobacterium / Q000187:drug effects / Q000235:genetics; D019818:Clavulanic Acid / Q000627:therapeutic use; D003013:Clostridium / Q000187:drug effects / Q000235:genetics; D017124:Conserved Sequence; D017931:DNA Primers; D004269:DNA, Bacterial / Q000235:genetics; D004755:Enterobacteriaceae / Q000187:drug effects / Q000235:genetics; D005051:Eubacterium / Q000187:drug effects / Q000235:genetics; D005243:Feces / Q000382:microbiology*; D006801:Humans; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D019936:Probiotics / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D017931:DNA Primers; D004269:DNA, Bacterial; D019818:Clavulanic Acid; D000658:Amoxicillin